Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ACHL | US
-0.01
-0.80%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.99
1.00
1.01
0.97
Achilles Therapeutics Plc a clinical stage immuno-oncology biopharmaceutical company develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London the United Kingdom.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
19.5%1 month
36.1%3 months
74.7%6 months
61.4%-
-
0.35
0.04
0.03
1.66
-
-
-65.90M
42.36M
42.36M
-
-
-
-
-44.22
0.20
1.42
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.08
Range1M
0.13
Range3M
0.45
Rel. volume
0.34
Price X volume
51.43K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Vor Biopharma Inc | VOR | Biotechnology | 0.6782 | 46.39M | -1.71% | n/a | 34.48% |
| CELU | CELU | Biotechnology | 2.105 | 46.28M | -16.14% | n/a | 127.38% |
| Rallybio Corporation Common Stock | RLYB | Biotechnology | 1.1 | 45.64M | -1.79% | n/a | 0.35% |
| Clene Nanomedicine Inc | CLNN | Biotechnology | 5.71 | 45.46M | 2.70% | n/a | -6472.02% |
| Rafael Holdings Inc | RFL | Biotechnology | 1.84 | 45.42M | -5.64% | n/a | 2.77% |
| LAVA Therapeutics BV | LVTX | Biotechnology | 1.7206 | 45.25M | 2.42% | n/a | 14.37% |
| CollPlant Holdings Ltd | CLGN | Biotechnology | 3.92 | 44.90M | -6.31% | n/a | 0.00% |
| CALC | CALC | Biotechnology | 4.12 | 44.29M | 0.98% | n/a | 0.00% |
| Immix Biopharma Inc. | IMMX | Biotechnology | 1.6 | 43.92M | -6.98% | n/a | 4.57% |
| Lexaria Bioscience Corp | LEXX | Biotechnology | 2.75 | 43.48M | -0.36% | n/a | 1.41% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 13.44 | 20.47M | 4.19% | n/a | 204.46% |
| ILAG | ILAG | Building Products & Equipment | 1 | 18.06M | -2.91% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
| Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.66 | - | Expensive |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.35 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 74.72 | - | Par |
| Debt to Equity | 0.04 | -1.23 | Expensive |
| Debt to Assets | 0.03 | 0.25 | Cheaper |
| Market Cap | 42.36M | - | Emerging |